Taysha Gene Therapies Inc [TSHA] stock prices are down -0.18% to $2.78 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TSHA shares have gain 6.72% over the last week, with a monthly amount glided 7.75%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Taysha Gene Therapies Inc [NASDAQ: TSHA] stock has seen the most recent analyst activity on June 27, 2024, when BMO Capital Markets initiated its Outperform rating and assigned the stock a price target of $5. Previously, Piper Sandler started tracking the stock with Overweight rating on April 09, 2024, and set its price target to $9. On February 01, 2023, downgrade downgraded it’s rating to Hold and revised its price target to $1.50 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight and decreased its price target to $3 on January 27, 2023. Goldman downgraded its rating to a Neutral and reduced its price target to $3 on November 09, 2022. Robert W. Baird started tracking with a Outperform rating for this stock on March 09, 2022, and assigned it a price target of $26. In a note dated March 01, 2022, Wells Fargo initiated an Overweight rating and provided a target price of $25 on this stock.
The stock price of Taysha Gene Therapies Inc [TSHA] has been fluctuating between $1.05 and $4.32 over the past year. Currently, Wall Street analysts expect the stock to reach $18.67 within the next 12 months. Taysha Gene Therapies Inc [NASDAQ: TSHA] shares were valued at $2.78 at the most recent close of the market. An investor can expect a potential return of 571.58% based on the average TSHA price forecast.
Analyzing the TSHA fundamentals
The Taysha Gene Therapies Inc [NASDAQ:TSHA] reported sales of 7.22M for trailing twelve months, representing a drop of -32.51%. Gross Profit Margin for this corporation currently stands at 0.73% with Operating Profit Margin at -12.26%, Pretax Profit Margin comes in at -12.01%, and Net Profit Margin reading is -12.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.63, Equity is -1.07 and Total Capital is -0.76. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.71 points at the first support level, and at 2.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.91, and for the 2nd resistance point, it is at 3.04.
Ratios To Look Out For
It’s worth pointing out that Taysha Gene Therapies Inc [NASDAQ:TSHA]’s Current Ratio is 5.35. In addition, the Quick Ratio stands at 5.35 and the Cash Ratio stands at 5.17. Considering the valuation of this stock, the price to sales ratio is 100.70, the price to book ratio is 10.35.
Transactions by insiders
Recent insider trading involved Manning Paul B, 10% Owner, that happened on May 30 ’25 when 0.75 million shares were purchased. 10% Owner, Manning Paul B completed a deal on Jun 27 ’24 to buy 1.33 million shares.
